<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533845</url>
  </required_header>
  <id_info>
    <org_study_id>07/02/VA13</org_study_id>
    <nct_id>NCT00533845</nct_id>
  </id_info>
  <brief_title>Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery</brief_title>
  <official_title>Intraperitoneal Bupivicaine Infusion Using the On-Q Pain Pump After Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      After Laparoscopic surgery most patients experience some form of mild to moderate pain. The
      current standard of care is to treat this pain with local anesthetics (numbing medication,
      that deadens the nerve endings) to the small surgical incisions (cuts) and narcotic systemic
      analgesics (medication injected into your vein to control pain such as morphine).

      Although this treatment improves pain symptoms it is not perfect. Firstly, complete pain
      control is rarely achieved and secondly, narcotics (such as morphine) often have many side
      effects including nausea, vomiting, sedation (sleepiness), constipation and abdominal upset.
      All of these issues make recovery less comfortable and delays return to full function (work,
      school and other activities of daily life).

      A new FDA approved device is now available that offers the benefits of long term anesthesia
      without the side effects of narcotics. It consists of a pump that continuously infuses local
      anesthesia into and around the surgical site. This pump is placed during your operation. You
      then carry a tennis ball sized container made of soft plastic in a pouch which drips numbing
      medicine around your wounds for 2 days continuously.

      The purpose of this study is to see if this pump improves postoperative pain, decreases the
      need for narcotic pain medicine and allows people to return to their activities earlier.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The procedure of the current study is to randomly assign patients undergoing minimally
      invasive surgeries (laparoscopic cholecystectomies and laparoscopic Lap-Banding procedures)
      to one of two groups. Both groups will have the standard surgical procedure performed and
      then at the completion will have the on-Q system placed in a subdiaphragmatic (within the
      abdomen) location. Half of the study group will have bupivicaine, a numbing medicine in the
      pump while the other half will have sterile saline in their pump. Neither the patient nor the
      surgeon will be aware of which group any particular patient is in, this is a process known as
      &quot;blinding&quot; and improves the reliability of the results. All patients will receive the
      standard locally infiltrated trocar site local anesthetic and either a prescription for
      Vicodin for ambulatory patients or morphine injected into their vein for patients staying in
      the hospital.

      All patients will then be asked at preset intervals their level of pain the presence of
      nausea and their need for Vicodin or morphine. Ambulatory patients will be reached by phone
      for answers to these questions. All patients will have their pain controlled in the usual and
      standard way at all times. The On-Q pump will be removed at 48hours.

      The results will then be statistically reviewed to see if the On-Q pumps were of benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Aanalog Scale (VAS) for Pain Assessment With Cough at 48 Hours</measure>
    <time_frame>48 hours postop</time_frame>
    <description>Pain assessment using a subjective pain visual analog scale VAS with cough at 48 hours. Participant will be shown a card that has a visual analogue (Faces) pains scale combined with numerical (0-10) analogue scale (0 is no pain, 10 is the worst pain imaginable).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>On-Q pain pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>On-Q Pain Pump</intervention_name>
    <description>Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally</description>
    <arm_group_label>On-Q pain pump</arm_group_label>
    <arm_group_label>Placebo/control</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing laparoscopic cholecystectomy or Lap-Band ASA III or less

        Exclusion Criteria:

          -  Patients who refuse consent

          -  Are converted from laparoscopy to open surgery

          -  Are allergic to bupivacaine

          -  Are unable to followup
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny A Sherwinter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>August 11, 2015</results_first_submitted>
  <results_first_submitted_qc>April 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Danny A Sherwinter</investigator_full_name>
    <investigator_title>Attending, Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1 participant randomized to bupivicaine did not complete the study because the participant had to be returned to surgery prior to commencement of study procedures</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Bupivacaine</title>
          <description>On-Q pump containing Bupivacaine implanted
On-Q Pain Pump: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally</description>
        </group>
        <group group_id="P2">
          <title>Placebo/Control</title>
          <description>Saline used in the implanted On-Q device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis - 30 enrolled but only 29 evaluated because patient required re-operative intervention with removal of experimental device precluding assessment of VAS pain scores</population>
      <group_list>
        <group group_id="B1">
          <title>Bupivacaine</title>
          <description>On-Q pump containing Bupivacaine implanted
On-Q Pain Pump: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally</description>
        </group>
        <group group_id="B2">
          <title>Placebo/Control</title>
          <description>Saline used in the implanted On-Q device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="9.7"/>
                    <measurement group_id="B2" value="42.0" spread="11.8"/>
                    <measurement group_id="B3" value="43.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Scale</title>
          <description>Likert scale ranging from 0 to 10 (0 being no pain and 10 being very severe pain)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread=".75"/>
                    <measurement group_id="B2" value="3.5" spread=".75"/>
                    <measurement group_id="B3" value="3.5" spread=".75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Aanalog Scale (VAS) for Pain Assessment With Cough at 48 Hours</title>
        <description>Pain assessment using a subjective pain visual analog scale VAS with cough at 48 hours. Participant will be shown a card that has a visual analogue (Faces) pains scale combined with numerical (0-10) analogue scale (0 is no pain, 10 is the worst pain imaginable).</description>
        <time_frame>48 hours postop</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine</title>
            <description>On-Q pump containing Bupivacaine implanted
On-Q Pain Pump: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally</description>
          </group>
          <group group_id="O2">
            <title>Placebo/Control</title>
            <description>Saline used in the implanted On-Q device</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Aanalog Scale (VAS) for Pain Assessment With Cough at 48 Hours</title>
          <description>Pain assessment using a subjective pain visual analog scale VAS with cough at 48 hours. Participant will be shown a card that has a visual analogue (Faces) pains scale combined with numerical (0-10) analogue scale (0 is no pain, 10 is the worst pain imaginable).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.94"/>
                    <measurement group_id="O2" value="3.9" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.0022</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bupivacaine</title>
          <description>On-Q pump containing Bupivacaine implanted
On-Q Pain Pump: Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally</description>
        </group>
        <group group_id="E2">
          <title>Placebo/Control</title>
          <description>Saline used in the implanted On-Q device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Danny A Sherwinter</name_or_title>
      <organization>Maimonides Medical center</organization>
      <phone>7182837952</phone>
      <email>dsherwinter@maimonidesmed.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

